Roland Tschismarov

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial.

A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial.

Journal: Vaccine
Published: April 07, 2023

Biodistribution and toxicology evaluation of a recombinant measles Schwarz-based Lassa vaccine in cynomolgus macaques.

Biodistribution and toxicology evaluation of a recombinant measles Schwarz-based Lassa vaccine in cynomolgus macaques.

Journal: Journal of applied toxicology : JAT
Published: November 17, 2022

Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.

Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.

Journal: Lancet (London, England)
Published: September 28, 2022

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.

Journal: EBioMedicine
Published: August 02, 2021

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

Journal: EBioMedicine
Published: August 02, 2021

Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine.

Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine.

Journal: JCI insight
Published: May 04, 2021

The AP-1 transcription factors c-Jun and JunB are essential for CD8α conventional dendritic cell identity.

The AP-1 transcription factors c-Jun and JunB are essential for CD8α conventional dendritic cell identity.

Journal: Cell death and differentiation
Published: October 28, 2020

Cutibacterium acnes Infection Induces Type I Interferon Synthesis Through the cGAS-STING Pathway.

Cutibacterium acnes Infection Induces Type I Interferon Synthesis Through the cGAS-STING Pathway.

Journal: Frontiers in immunology
Published: June 10, 2020

Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.

Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.

Journal: Frontiers in immunology
Published: December 15, 2019

Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation.

Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation.

Journal: JCI insight
Published: September 10, 2019

Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.

Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.

Journal: The Journal of infectious diseases
Published: August 19, 2019

Intracellular bacteria engage a STING-TBK1-MVB12b pathway to enable paracrine cGAS-STING signalling.

Intracellular bacteria engage a STING-TBK1-MVB12b pathway to enable paracrine cGAS-STING signalling.

Journal: Nature microbiology
Published: September 25, 2018
Showing 1-12 of 17

Last Updated: 09/26/2026